These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 30259707)

  • 1. Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation.
    Cirincione B; Kowalski K; Nielsen J; Roy A; Thanneer N; Byon W; Boyd R; Wang X; Leil T; LaCreta F; Ueno T; Oishi M; Frost C
    CPT Pharmacometrics Syst Pharmacol; 2018 Nov; 7(11):728-738. PubMed ID: 30259707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
    Otsuka Y; Choules MP; Bonate PL; Komatsu K
    CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):659-669. PubMed ID: 33030266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors for a high apixaban level in elderly patients with atrial fibrillation prescribed reduced dose of apixaban.
    Suzuki S; Yamashita T; Akao M; Okumura K
    Eur J Clin Pharmacol; 2021 Nov; 77(11):1757-1758. PubMed ID: 34014337
    [No Abstract]   [Full Text] [Related]  

  • 4. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation.
    Ueshima S; Hira D; Kimura Y; Fujii R; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Ohno S; Horie M; Terada T; Katsura T
    Br J Clin Pharmacol; 2018 Jun; 84(6):1301-1312. PubMed ID: 29457840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics and Pharmacodynamics of Apixaban Linking Its Plasma Concentration to Intrinsic Activated Coagulation Factor X Activity in Japanese Patients with Atrial Fibrillation.
    Ueshima S; Hira D; Tomitsuka C; Nomura M; Kimura Y; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Horie M; Terada T; Katsura T
    AAPS J; 2019 Jun; 21(5):80. PubMed ID: 31236790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
    Frost CE; Byon W; Song Y; Wang J; Schuster AE; Boyd RA; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
    Br J Clin Pharmacol; 2015 May; 79(5):838-46. PubMed ID: 25377242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism.
    Byon W; Sweeney K; Frost C; Boyd RA
    CPT Pharmacometrics Syst Pharmacol; 2017 May; 6(5):340-349. PubMed ID: 28547774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of apixaban on antifactor Xa levels in a patient with acute kidney injury.
    Wendte J; Voss G; VanOverschelde B
    Am J Health Syst Pharm; 2016 Apr; 73(8):563-7. PubMed ID: 27045068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial.
    Krekels EH; Niebecker R; Karlsson MO; Miller R; Shimizu T; Karlsson KE; Ruff CT; Simonsson US; Jönsson S
    Clin Pharmacokinet; 2016 Sep; 55(9):1079-90. PubMed ID: 26951208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation.
    Lin SY; Kuo CH; Yeh SJ; Tsai LK; Liu YB; Huang CF; Tang SC; Jeng JS
    Clin Pharmacol Ther; 2020 Jan; 107(1):278-286. PubMed ID: 31376150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban.
    Frost CE; Song Y; Shenker A; Wang J; Barrett YC; Schuster A; Harris SI; LaCreta F
    Clin Pharmacokinet; 2015 Jun; 54(6):651-62. PubMed ID: 25573421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety outcomes of apixaban in patients with nonvalvular atrial fibrillation and severe renal impairment.
    Jones MJ; Eudaley ST; Moye RA; Hodge TA; Nesbit RM; Franks AS
    J Thromb Thrombolysis; 2020 Aug; 50(2):330-336. PubMed ID: 31902123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
    Hellwig T; Gulseth M
    Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of Apixaban-Treated Patients, Evaluation of the Dose Prescribed, and the Persistence of Treatment: A Cohort Study in Catalonia.
    Gomez-Lumbreras A; Cortes J; Giner-Soriano M; Quijada-Manuitt MA; Morros R
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):494-501. PubMed ID: 29792125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apixaban: a new factor Xa inhibitor for stroke prevention in patients with nonvalvular atrial fibrillation.
    Lam S
    Cardiol Rev; 2013; 21(4):207-12. PubMed ID: 23535530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Safety of Apixaban Versus Rivaroxaban for Patients With Atrial Fibrillation.
    Ann Intern Med; 2020 Apr; 172(7):. PubMed ID: 32150747
    [No Abstract]   [Full Text] [Related]  

  • 17. Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients.
    Mavrakanas TA; Samer CF; Nessim SJ; Frisch G; Lipman ML
    J Am Soc Nephrol; 2017 Jul; 28(7):2241-2248. PubMed ID: 28302754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
    Mikus G; Foerster KI; Schaumaeker M; Lehmann ML; Burhenne J; Haefeli WE
    Clin Pharmacokinet; 2019 Sep; 58(9):1155-1163. PubMed ID: 30828771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
    Kreutz R; Persson PB; Kubitza D; Thelen K; Heitmeier S; Schwers S; Becka M; Hemmrich M
    J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German Practice.
    Coleman CI; Peacock WF; Antz M
    Heart Lung Circ; 2018 Mar; 27(3):390-393. PubMed ID: 28528780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.